The company that spent years in American courtrooms as the defendant is now turning the tables. Bayer has filed patent claims against Pfizer and Moderna over mRNA optimization technologies originally developed at Monsanto — a striking reversal for a firm whose name has become synonymous with glyphosate litigation. The offensive marks an attempt to finally monetize the costly Monsanto acquisition beyond its agricultural roots, transforming what was once a source of writedowns and legal risk into a potential revenue stream.
Yet even as Bayer presses its new legal claims, the old ones refuse to fade quietly. All eyes are now fixed on August 19, 2026, when a St. Louis court will rule on final approval of the multibillion-dollar class-action settlement covering glyphosate lawsuits. The hearing was originally scheduled for early July but was postponed by the court. A favorable ruling could allow the company to cap its US legal exposure once and for all; an unfavorable one would reopen uncertainty for shareholders.
A Supreme Court Shift Reshapes the Legal Landscape
The dynamics shifted dramatically on June 25, 2026, when the US Supreme Court ruled in the “Durnell” case that federal requirements take precedence over state-level warning claims. Bayer has moved swiftly to exploit the decision, filing motions with US federal courts to dismiss thousands of pending glyphosate cases. It is a significant procedural victory — but not yet a final clearing of the decks. The real test comes with the August hearing.
The central question hanging over the company: Can Bayer secure permanent financial closure on its US legal liabilities through court approval of the settlement? Or will the negotiated compromise collapse under judicial skepticism or insufficient claimant participation? Only after clearing this hurdle, analysts suggest, can management reclaim the planning certainty needed for its operational turnaround.
The Market Has Already Priced in Optimism
Investors have not waited for the verdict. The stock has climbed 31 percent since the start of the year and an eye-catching 78 percent over twelve months. Trading comfortably above its 200-day moving average of €39.20, the shares show a healthy medium-term uptrend. The relative strength index sits at 59.5 — elevated but not overbought, suggesting chart room for further gains should the settlement receive approval in August.
The market capitalization now stands at roughly €48 billion, with the stock trading 23.69 percent above its 200-day average. A weekly gain of 5.48 percent underscores the momentum, yet the technical indicators still point to upside potential rather than exhaustion.
Beyond the legal front, balance sheet work is supporting the rally. CFO Judith Hartmann continues to drive restructuring efforts, including multibillion-dollar US dollar bond issuances to refinance maturing debt and an equity deal with asset manager Apollo to shore up liquidity. These moves would give management greater strategic flexibility.
The Bear Case: Even Victory Carries a Price
But the bull narrative has its limits. Even if the court approves the settlement, the matter is not immediately closed. The agreed compensation will be paid in installments spread over several decades, weighing on free cash flow and the balance sheet for years to come.
Should investors sell immediately? Or is it worth buying Bayer?
The shares have already shown signs of cooling, slipping 0.57 percent over the past 30 days. More tellingly, annualized volatility above 61 percent marks Bayer as a highly speculative bet — an extraordinary figure for a DAX constituent. The stock has effectively become a leveraged wager on the litigation outcome.
Operational headwinds persist as well. The agriculture division is consolidating its breeding activities in Hawaii, with dozens of positions slated for elimination from late September 2026. Should this operational weakness deepen, or should the planned divestment of smaller business units stall, the positive effect of legal relief could be diluted.
A Broader Transformation Takes Shape
Meanwhile, Bayer is pushing forward on multiple fronts. The company has filed a regulatory application in China for Kerendia, a treatment for non-diabetic chronic kidney disease. With up to 15 percent of Chinese adults affected by some form of CKD, according to company data, the move represents a calculated bet on a mass-market problem in the world’s second-largest economy.
In agriculture, the strategy is shifting from volume herbicide sales toward higher-value offerings. The new product “Pack MD Diag+” combines herbicides with qPCR-based diagnostic tools deployed directly in the field — selling data and efficiency rather than chemicals alone. It is exactly the kind of margin defense needed in a volatile agricultural market.
These initiatives share a common thread: Bayer is no longer waiting for its legal legacy to resolve before acting. The company is pressing forward on multiple fronts while the old liabilities grind on in the background.
Two August Dates Will Define the Next Phase
The coming weeks carry unusual weight. Before the St. Louis ruling arrives, Bayer publishes its first-half results on Tuesday, August 4. Those numbers will reveal whether CEO Bill Anderson’s restructuring pace is matching investor expectations — or whether the share price has run ahead of fundamentals.
Should the stock hold its technical supports at the 50-day and 200-day moving averages, the bullish momentum argues for a continuation of the recovery, with a retest of the 52-week high at €53.86 within reach. Should the court reject the settlement or demand unreasonable modifications, however, a rapid correction could follow, putting the hard-won gains of recent months at risk.
For a company that has spent years on the defensive, the irony is not lost: Bayer now finds itself playing offense in court while simultaneously awaiting a ruling that could determine its financial trajectory for decades. The August 19 decision remains the pivotal date — the moment when the market will learn whether the long road back to stability has finally reached its destination.
Ad
Bayer Stock: Buy or Sell?! New Bayer Analysis from August 1 delivers the answer:
The latest Bayer figures speak for themselves: Urgent action needed for Bayer investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from August 1.
Bayer: Buy or sell? Read more here...
